Bill > S4635

This bill, the Pharmaceutical Risk Assessment and Mitigation Act of 2024, requires the Under Secretary of Defense for Acquisition and Sustainment to submit a report to Congress on the Department of Defense's (DoD) reliance on high-risk foreign suppliers for pharmaceutical ingredients and drug products. The report must include information on existing government data streams, details on which manufacturers in high-risk countries produce active pharmaceutical ingredients and final drug products used by the DoD, limitations on the DoD's ability to obtain and analyze this information, and recommendations to address these limitations. The bill also requires the Under Secretary to update the risk management guidance developed under a previous law to incorporate relevant findings from the report. Additionally, the bill states that the DoD shall rely on determinations made by the Food and Drug Administration (FDA) regarding excipients and key starting materials for final drug products.

Military Affairs and Security

https://www.congress.gov/bill/118th-congress/senate-bill/4635/all-info